X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13214) 13214
Book Review (2341) 2341
Publication (820) 820
Newsletter (719) 719
Newspaper Article (586) 586
Magazine Article (112) 112
Book Chapter (97) 97
Conference Proceeding (96) 96
Reference (42) 42
Book / eBook (41) 41
Dissertation (37) 37
Transcript (11) 11
Government Document (9) 9
Web Resource (9) 9
Trade Publication Article (7) 7
Streaming Video (6) 6
Video Recording (2) 2
Archival Material (1) 1
Data Set (1) 1
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9264) 9264
humans (9070) 9070
thalidomide (8640) 8640
female (4508) 4508
male (4402) 4402
thalidomide - therapeutic use (3859) 3859
middle aged (3081) 3081
thalidomide - analogs & derivatives (2871) 2871
oncology (2829) 2829
aged (2667) 2667
multiple myeloma (2623) 2623
hematology (2606) 2606
multiple myeloma - drug therapy (2472) 2472
adult (2391) 2391
thalidomide - adverse effects (2327) 2327
thalidomide - administration & dosage (2169) 2169
animals (1950) 1950
treatment outcome (1934) 1934
bortezomib (1708) 1708
lenalidomide (1638) 1638
antineoplastic combined chemotherapy protocols - therapeutic use (1545) 1545
therapy (1506) 1506
thalidomide - pharmacology (1430) 1430
care and treatment (1256) 1256
cancer (1208) 1208
antineoplastic agents - therapeutic use (1174) 1174
research (1101) 1101
dexamethasone (1089) 1089
chemotherapy (1057) 1057
aged, 80 and over (1014) 1014
abridged index medicus (989) 989
stem-cell transplantation (978) 978
pharmacology & pharmacy (970) 970
drug therapy (928) 928
dexamethasone - administration & dosage (826) 826
pregnancy (826) 826
multiple-myeloma (823) 823
survival (807) 807
angiogenesis inhibitors - therapeutic use (798) 798
aids/hiv (792) 792
mice (792) 792
immunosuppressive agents - therapeutic use (759) 759
angiogenesis (750) 750
prognosis (705) 705
multiple myeloma - pathology (698) 698
multiple myeloma - therapy (691) 691
transplantation (671) 671
recurrence (650) 650
multiple myeloma - mortality (642) 642
medicine & public health (635) 635
health aspects (621) 621
analysis (618) 618
medicine, general & internal (609) 609
antineoplastic combined chemotherapy protocols - adverse effects (575) 575
disease-free survival (568) 568
trial (539) 539
retrospective studies (537) 537
risk factors (532) 532
rats (528) 528
dose-response relationship, drug (522) 522
dermatology (520) 520
abnormalities, drug-induced (519) 519
immunology (514) 514
clinical trials as topic (494) 494
drug therapy, combination (478) 478
necrosis-factor-alpha (476) 476
expression (474) 474
follow-up studies (472) 472
remission induction (458) 458
hematology, oncology and palliative medicine (457) 457
toxicology (452) 452
dosage and administration (449) 449
immunologic factors - therapeutic use (445) 445
survival analysis (445) 445
antineoplastic agents - adverse effects (444) 444
melphalan (437) 437
multiple myeloma - diagnosis (432) 432
drugs (431) 431
old medline (431) 431
combination (426) 426
time factors (426) 426
transplantation, autologous (422) 422
myeloma (415) 415
boronic acids - administration & dosage (412) 412
pyrazines - administration & dosage (411) 411
survival rate (406) 406
medical research (405) 405
antineoplastic combined chemotherapy protocols - administration & dosage (404) 404
disease progression (404) 404
clinical trials (399) 399
cells (398) 398
adolescent (394) 394
diagnosis (390) 390
multiple myeloma - complications (388) 388
plus dexamethasone (387) 387
stem cells (380) 380
boronic acids - therapeutic use (375) 375
pyrazines - therapeutic use (375) 375
combined modality therapy (373) 373
child (370) 370
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (17) 17
Robarts - Stacks (9) 9
UTL at Downsview - May be requested (7) 7
Online Resources - Online (5) 5
OISE - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Law (Bora Laskin) - May be requested in 6-10 wks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Trinity College (John W Graham) - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Media Commons - Audio Visual (2) 2
UofT at Mississauga - Stacks (2) 2
Criminology - Stacks (1) 1
East Asian (Cheng Yu Tung) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Music - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13089) 13089
German (484) 484
French (317) 317
Japanese (241) 241
Chinese (157) 157
Spanish (145) 145
Italian (85) 85
Portuguese (76) 76
Polish (70) 70
Czech (55) 55
Swedish (35) 35
Korean (34) 34
Dutch (25) 25
Russian (22) 22
Danish (14) 14
Hungarian (12) 12
Norwegian (8) 8
Finnish (7) 7
Hebrew (7) 7
Turkish (7) 7
Serbian (4) 4
Slovak (4) 4
Ukrainian (4) 4
Romanian (3) 3
Slovenian (3) 3
Bosnian (1) 1
Bulgarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cytokine, ISSN 1043-4666, 11/2014, Volume 70, Issue 1, p. 59
The Teratogenic properties of Thalidomide, in addition to its efficacy in the treatment of Multiple Myeloma, are dependent on Cereblon. Importantly however,... 
Thalidomide
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 906 - 917
Journal Article
Cellular Signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in... 
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | PROTEIN-KINASE-A | CONTROLLED-TRIAL | CAMP-SPECIFIC PHOSPHODIESTERASE | NECROSIS-FACTOR-ALPHA | KAPPA-B | PSORIATIC-ARTHRITIS | CELL BIOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | CYCLIC-AMP | THALIDOMIDE ANALOGS | B-MEDIATED TRANSCRIPTION | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2002, Volume 100, Issue 9, pp. 3063 - 3067
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 18, pp. 4771 - 4779
Journal Article
Leukemia Research, ISSN 0145-2126, 07/2009, Volume 33, Issue 7, pp. 970 - 973
The chemokine stromal-derived factor-1? (SDF-1?) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple... 
Thalidomide
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 11, pp. 1961 - 1967
Journal Article
Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 11, pp. 2970 - 2975
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1770 - 1781
Journal Article
Journal Article
Blood, ISSN 0006-4971, 01/2012, Volume 119, Issue 4, pp. 933 - 939
Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism... 
TRIAL | PROPHYLAXIS | THERAPY | PLUS DEXAMETHASONE | VENOUS THROMBOSIS | PREVENTION | THALIDOMIDE | THROMBOEMBOLISM | HEMATOLOGY | CANCER | CHEMOTHERAPY | Pulmonary Embolism - prevention & control | Venous Thrombosis - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Incidence | Thalidomide - analogs & derivatives | Venous Thromboembolism - prevention & control | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Aspirin - adverse effects | Adult | Female | Venous Thrombosis - prevention & control | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Venous Thromboembolism - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Thalidomide - adverse effects | Risk Factors | Anticoagulants - therapeutic use | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Israel - epidemiology | Venous Thrombosis - epidemiology | Venous Thromboembolism - chemically induced | Italy - epidemiology | Pulmonary Embolism - chemically induced | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article